Clinical Trial

131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)

Study acronym: IPAX-2
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is an open label, single arm, parallel-group, multicentre, and dose finding study to evaluate the safety of ascending radioactive dose levels of 131I-TLX101 administered intravenously in combination with best standard of care in newly diagnosed GBM patients.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-14
notable Primary completion pushed: 2026-06 -> 2027-06 2026-08-14
minor Completion pushed: 2026-06 -> 2027-06 2026-08-14
Trial Details
NCT Number NCT05450744
Lead Sponsor Telix Pharmaceuticals (Innovations) Pty Limited
Conditions Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme
Enrollment 12 participants
Start Date 2023-04-01
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-13